Johnson & Johnson Drug Receives Positive Data in Trials (JNJ)

Johnson & Johnson Drug Receives Positive Data in Trials (JNJ)


According to data being presented at a medical meeting in Europe, Johnson & Johnson’s (JNJ) new drug to combat psoriatic arthritis, Stelara, has produced positive results in recent testing and trials.

Through 52 weeks of treatment the drug has produced significant improvements in psoriatic arthritis symptoms.

Psoriatic arthritis is a chronic inflammatory condition in which joint pain is caused by the immune system attacking healthy tissues. Many patients are treated with anti-TNF drugs such as AbbVie’s (ABBV) Humira and Johnson & Johnson’s own Remicade.

Johnson & Johnson shares were up 31 cents, or +0.37%, during pre-market trading on Wednesday. The stock is up +20.81% year-to-date.

The Bottom Line
Shares of Johnson & Johnson (JNJ) have a dividend yield of 3.12% based on last night’s closing price of $84.69 and the company’s annualized dividend payout of $2.64 per share.

Johnson & Johnson (JNJ) is not recommended at this time, holding a DARS™ Rating of 3.4 out of 5 stars.

Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.

Free Updates

Join over 100,000 investors who get the latest news from

Best Dividend Stocks

Looking for stocks that are poised for growth and pay solid dividends? Visit our list of the:

Best Dividend Stocks

Partner Center

Best CD Rates

Sitting on some extra cash and looking for the most current and profitable CD Rates?

Get The Best CD Rates

14 Day Free Trial

Earn more from your dividend portfolio within the next 14 days.

Sign Up Today